27419 Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study

Abstract

Background: Long-term use of systemic treatments for atopic dermatitis (AD) typically requires laboratory monitoring for patient safety. Dupilumab studies have shown a favorable long-term efficacy and safety profile in adults with moderate-to-severe AD. Here, we present long-term laboratory safety from dupilumab-treated adults with moderate-to-severe AD in an OLE study.